Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Molecular Partners Ag (MOLN) over the last 5 years, with Sep 2025 value amounting to $102,955.

  • Molecular Partners Ag's Cash & Equivalents rose 35.66% to $102,955 in Q3 2025 from the same period last year, while for Sep 2025 it was $102,955, marking a year-over-year increase of 35.66%. This contributed to the annual value of $72.6 million for FY2024, which is 3.12% down from last year.
  • As of Q3 2025, Molecular Partners Ag's Cash & Equivalents stood at $102,955, which was up 3.98% from $99,017 recorded in Q2 2025.
  • In the past 5 years, Molecular Partners Ag's Cash & Equivalents registered a high of $91.3 million during Q4 2022, and its lowest value of $70,337 during Q2 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $79,930 (2023), whereas its average is $13.6 million.
  • In the last 5 years, Molecular Partners Ag's Cash & Equivalents slumped by 48.02% in 2023 and then surged by 36.32% in 2025.
  • Over the past 5 years, Molecular Partners Ag's Cash & Equivalents (Quarterly) stood at $77.9 million in 2021, then increased by 17.22% to $91.3 million in 2022, then decreased by 16.88% to $75.9 million in 2023, then fell by 3.91% to $72.9 million in 2024, then spiked by 35.66% to $102,955 in 2025.
  • Its Cash & Equivalents stands at $102,955 for Q3 2025, versus $99,017 for Q2 2025 and $90,505 for Q1 2025.